The PharmEase Group Acquires RAM Pharma (now Compound Preferred)

Revelation Pharma (Osceola Capital) Acquires Five Compounding Pharmacies

January 27, 2022

Healthcare Services

Revelation Pharma, a PE-backed specialty pharmacy platform sponsored by Osceola Capital, completed add-on acquisitions of five compounding pharmacies: Innovation Compounding, Pencol Compounding Pharmacy, Pharmacy Specialists Compounding, Wise Pharmacy, and Convex Pharmacy. The deals expand Revelation's geographic footprint and clinical capabilities across key U.S. regions and will see some locations merged into existing Revelation businesses (e.g., Wise into Pencol; Convex into Everwell).

HEXPOL Acquires Preferred Compounding from Audax Private Equity

July 23, 2019

Manufacturing

Sweden-based HEXPOL has acquired Preferred Compounding Corporation, a Copley, Ohio–headquartered custom rubber compounding company, from Audax Private Equity (in partnership with management). The deal — reported at roughly $232 million — expands HEXPOL’s advanced compounding capabilities and North American footprint; Preferred supplies proprietary and custom mixed rubber compounds to automotive, general industrial and infrastructure end markets.

Creative Foam Acquires RAM Technologies

July 23, 2021

Manufacturing

Creative Foam Corporation, a portfolio company of Industrial Opportunity Partners, has acquired the assets of RAM Technologies. The acquisition expands Creative Foam's Healthcare division capabilities and customer base coast-to-coast by adding RAM's foam, plastic and nonwoven converting and fabrication capabilities; terms were not disclosed.

Aquiline Makes Majority Investment in Pharma Force Group LLC

December 31, 2023

Healthcare Services

Aquiline Capital Partners has made a majority investment in Pharma Force Group LLC, a U.S.-based provider of 340B administration software and pharmacy benefits management solutions. The partnership will support PharmaForce’s product expansion and strategic M&A plans to accelerate growth across hospitals and health clinics. Piper Sandler advised PharmaForce; transaction closed in Q4 2023 with financial terms undisclosed.

Fagron Acquires University Compounding Pharmacy (UCP)

January 12, 2026

Pharmaceuticals

Fagron NV has completed the acquisition of University Compounding Pharmacy (UCP), a San Diego–based 503A compounding pharmacy focused on health and wellness, hormones and urology. The transaction has an enterprise value of approximately $41.5 million; UCP had annual revenues of around $25 million and will be integrated to strengthen Fagron's U.S. compounding platform alongside Anazao, with synergies expected over 18–24 months.

Fagron Completes Acquisition of University Compounding Pharmacy (UCP)

January 12, 2026

Pharmaceuticals

Fagron has completed the acquisition of University Compounding Pharmacy (UCP), a San Diego–based 503A compounding pharmacy focused on hormone and urology therapies. The transaction values UCP at approximately $41.5 million; UCP generates roughly $25 million of annual revenue. Fagron said the purchase supports its strategy to build a nationwide U.S. compounding platform (complementary to Anazao) and strengthens its presence in California.